Manageart has presented to media the study “Footprint of the Pharma Industry in Spain” commissioned by Farmaindustria, the Spanish Association of the Pharmaceutical Industry.
This is the first study of its kind carried out in Spain, and it has identified the 173 manufacturing sites established in Spain.
The report includes a map with the location of all the plants throughout the Spanish territory, classified according to the type of plant, which can be consulted at this link. 62% of the 173 plants (106) belong to Spanish companies, 22% (37) to Europeans and the remaining 17% (30) to groups from outside Europe.
The study highlights the 36,338 direct jobs generated in 2022, and the accumulated growth of the sector of 4.2% since 2019, as well as the drag effect generated in other sectors.
The analysis also highlights the high investment that companies make in their plants, averaging almost one billion euros per year in the last five years. According to estimates, the industry will have invested more than 4,800 million euros in its plants in the 2019-2023 period, which represents an investment rate on net assets of more than 20% per year.
The environmental sustainability of the production plants has been the other major priority in recent years in the sector, the result of which has been the improvement of energy efficiency and the reduction of energy consumption per employee by 8% in three years. In addition, industrial plants are becoming aware of the importance of guaranteeing the origin of the energy they consume achieving almost 70% of green energy.
The study performs a strategic analysis of the sector, identifying the strengths of the sector as well as the challenges for the future. Spanish pharmaceutical plants are recognized for their high-quality standards and competitive costs, as well as for the talent of their employees. However, the sector has various challenges ahead, among which stand out the challenge of strengthening its supply chain by reducing foreign dependence, especially Asia, improving its efficiency to counteract the general increase in supply prices and boosting the development of production plants for products based on biotechnology, among others.